Pain & Central Nervous System Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain & Central Nervous System Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Panic Disorder
Alexza Reports Third Quarter Financial Results and Updates Development of Product Candidates
November 19th, 2007
Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) reported financial results for its third fiscal quarter and the nine-month period ended September 30, 2007, and provided an update on the Company's progress with its development programs. The net loss for the 2007 third fiscal quarter and for the nine-month period ended September 30, 2007, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $10.8 million and $31.9 million, respectively, compared to a net loss of $11.2 million and $30.2 million in the comparable periods in 2006, respectively. Product Candidate Development and Corporate Goals Update -- AZ-004 (Staccato(R) loxapine) is initially...
Source: Pain & Central Nervous System Week (2007-11-19)
|
